Table Info

Table 2.

Comparison of patient characteristics with functional vs. non-functional tumors

Characteristic	Functional	Non-functional	P value
Number of patients	29	29	-
Mean age (years)	60	59	0.8
Male (%)	62%	55%	0.8
Small bowel primary	14 (48%)	10 (34%)	0.4
Pancreatic primary	4 (24%)	10 (34%)	0.1
Liver metastasis present	22 (76%)	26 (90%)	0.3
Grade 1	13 (45%)	9 (31%)	0.4
Grade 2	8 (28%)	16 (55%)	0.1
Prior somatostatin analogue treatment	27 (93%)	22 (76%)	0.1
Prior chemotherapy treatment	5 (17%)	12 (41%)	0.1

-: not applicable

Declarations

Author contributions

AK and SH: Conceptualization, Writing—review & editing. KM, RMTAR, AS, JCB, SKW, WS, AK, and SH: Data curation. KM and SH: Formal analysis. SH: Writing—original draft.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

A proposal was submitted to the Kansas University Medical Center IRB and accepted. Associated ethical IRB number: STUDY00147410. The manuscript complies with the declaration of Helsinki.

Consent to participate

The requirement of patients’ consent to participate is waived by the Kansas University internal review board due to the retrospective nature of the manuscript.

Consent to publication

Not applicable.

Availability of data and materials

The datasets for this manuscript are not publicly available as it contains patient health-protected information. Requests for accessing the datasets should be directed to the corresponding author Anup Kasi, akasi@kumc.edu.

Funding

Not applicable.

Copyright

@ The Author(s) 2023.

References

Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629–38. [DOI] [PubMed] [PMC]

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. [DOI] [PubMed]

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42. [DOI] [PubMed] [PMC]

Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al.; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76. [DOI] [PubMed]

Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, et al.; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42:557–77. [DOI] [PubMed] [PMC]

Neuroendocrine and adrenal tumors [Internet]. Pennsylvania: National Comprehensive Cancer Network; c2023 [cited 2022 Mar 28]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448

Pavel M, Baudin E, Öberg K, Hainsworth J, Voi M, Rouyrre N, et al. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol. 2017;28:1569–75. Erratum in: Ann Oncol. 2019;30:2010. [DOI] [PubMed] [PMC]

Kwekkeboom DJ, Kam BL, Van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53–73. [DOI] [PubMed]

FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS [Internet]. Washington, D.C.: FDA Organization; [cited 2022 Mar 28]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-treatment-gep-nets

10.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al.; NETTER-1 Trial Investigators. Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. [DOI] [PubMed] [PMC]

11.

Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617–24. [DOI] [PubMed]

12.

Zhang J, Song Q, Cai L, Xie Y, Chen Y. The efficacy of ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2020;146:1533–43. [DOI] [PubMed]

13.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. [DOI] [PubMed]

14.

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al.; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8. [DOI] [PubMed] [PMC]

15.

Schmidt C, Bloomston M, Shah MH. Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies. Oncogene. 2011;30:1497–505. [DOI] [PubMed] [PMC]

16.

Lord SR, Hall PS, Seymour MT. Are we representing the true population in oncology trials? Ann Oncol. 2009;20:2022. [DOI] [PubMed]

17.

Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res. 2013;19:2629–36. [DOI] [PubMed] [PMC]

18.

Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95:3276–81. [DOI] [PubMed]

19.

Pavel M, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, et al.; Vienna Consensus Conference participants. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85. [DOI] [PubMed]

20.

Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al.; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005–12. [DOI] [PubMed]

21.

Janson ET, Öberg K. Long-term management of the carcinoid syndrome treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32:225–9. [DOI] [PubMed]

22.

Gleisner KS, Brolin G, Sundlöv A, Mjekiqi E, Östlund K, Tennvall J, et al. Long-term retention of ¹⁷⁷Lu/^177mLu-DOTATATE in patients investigated by γ-spectrometry and γ-camera imaging. J Nucl Med. 2015;56:976–84. [DOI] [PubMed]

23.

Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 2020;6:1086–92. [DOI] [PubMed]

24.

Bergsma H, van Lom K, Raaijmakers M, Konijnenberg M, Kam B, Teunissen JJM, et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with ¹⁷⁷Lu -DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2018;59:452–8. [DOI] [PubMed]

25.

Li J, Luo G, Fu D, Jin C, Hao S, Yang F, et al. Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors. Med Oncol. 2011;28:1027–31. [DOI] [PubMed]

26.

Nomura N, Fujii T, Kanazumi N, Takeda S, Nomoto S, Kasuya H, et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg. 2009;16:639–47. [DOI] [PubMed]

27.

Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633–42. [DOI] [PubMed]

28.

Broughan TA, Leslie JD, Soto JM, Hermann RE. Pancreatic islet cell tumors. Surgery. 1986;99:671–8. [PubMed]

29.

Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery. 1988;104:1011–7. [PubMed]

30.

Phase II study of peptide receptor radionuclide therapy in combination with immunotherapy for patients with merkel cell cancer (iPRRT) [Internet]. Bethesda: National Library of Medicine; [cited 2022 Oct 12]. Available from: https://ClinicalTrials.gov/show/NCT05583708

31.

177Lutethium - peptide receptor radionuclide therapy (Lu-PRRT) plus capecitabine versus Lu-PRRT in FDG positive, gastro-entero-pancreatic neuroendocrine tumors (Lu-Ca-S)[Internet]. Bethesda: National Library of Medicine; [cited 2022 Oct 12]. Available from: https://ClinicalTrials.gov/show/NCT02736448